In a deal valued at £550,000, ANGLE plc (AIM:AGL, OTCQX:ANPCY), a leading liquid biopsy company specializing in circulating tumor cell (CTC) solutions, has secured an agreement with AstraZeneca (LSE/STO/Nasdaq: AZN) to develop a Parsortix-based Androgen Receptor (AR) detection assay for prostate cancer studies. The assay will be developed in ANGLE’s UK laboratories, and its successful […]
ANGLE plc, a leading innovator in liquid biopsy and circulating tumour cell (CTC) solutions, has announced a significant supplier agreement with global biopharmaceutical leader AstraZeneca PLC. The collaboration focuses on developing a novel methodology for the detection of micronuclei in CTCs, utilizing ANGLE’s DNA damage response (DDR) assay, a key marker in cancer diagnostics and […]
ANGLE plc, a global leader in liquid biopsy technology, has recently achieved a major breakthrough in cancer diagnostics, unveiling results from DNA molecular analysis of patient blood samples. These results provide an unprecedented insight into the individual progression of cancer and open new avenues for treatment. Revolutionizing Cancer Diagnostics with Parsortix System ANGLE’s expansion of […]
UK-based liquid biopsy company ANGLE plc has won a pharma services contract worth up to $1.2 million from an undisclosed pharma company that is engaged in developing cancer drugs. The pharma company has chosen ANGLE’s Parsortix system to carry out longitudinal monitoring of patients in three separate clinical trials in prostate cancer and other locally […]
